Mentoring in Translational Research in Interstitial Lung Diseases

间质性肺疾病转化研究的指导

• 批准号: 9270690
• 负责人: Wonder P. Drake
• 金额: $ 10.69万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-02-15 至 2021-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9270690
• 关键词: Antigens; Antimycobacterial Agents; Biological Assay; CD28 gene; CD4 Positive T Lymphocytes; Candidate Disease Gene; Cell physiology; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Communicable Diseases; Cryptococcus neoformans infection; DNA Methylation; Data Collection; Defect; Disease; Disease Progression; Down-Regulation; Employee Strikes; Epigenetic Process; Family; Foundations; Functional disorder; Funding; Gene-Modified; Genes; Genomics; Grant; Granuloma; Granulomatous; HIV; Health; Helicobacter pylori; Immune; Immunologics; In Vitro; Inflammatory; Interleukin-2; Interstitial Lung Diseases; Intervention Studies; Investigation; K-Series Research Career Programs; Laboratories; Lead; Leadership; Leucine; Ligation; Link; Lung; Lung diseases; Manuscripts; Mass Spectrum Analysis; Mediator of activation protein; Mentored Research Scientist Development Award; Mentors; Microarray Analysis; Midcareer Investigator Award in Patient-Oriented Research; Modification; Molecular; Morbidity - disease rate; Nature; Outcome; Pathogenesis; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Phase; Placebo Control; Positioning Attribute; Principal Investigator; Publications; Randomized; Receptor Signaling; Regulation; Reporting; Research; Research Design; Research Project Grants; Resolution; Role; Sarcoidosis; Scientist; Signal Transduction; Stomach; Susceptibility Gene; T Cell Receptor Signaling Pathway; T-Cell Receptor; T-Lymphocyte; Therapeutic; Therapeutic Intervention; Time; Training; Transcription Factor AP-1; Translating; Translational Research; Translations; Tuberculosis; Universities; Up-Regulation; Vital capacity; Wood material; Work; career; clinical investigation; common cellular transcription factor ATF; cytokine; design; epigenomics; experience; immune function; medical schools; member; microbial; microorganism antigen; mid-career faculty; mortality; mouse model; mycobacterial; novel therapeutic intervention; novel therapeutics; patient oriented research; programs; research and development; response; restoration; transcription factor

 DESCRIPTION (provided by applicant): This is a proposal to provide protected time for Dr. Drake to provide greater mentoring to junior clinical investigators as well as increase her capacity to expand her clinical investigations in interstitial lung disease. Dr. Drake proposes a mentoring plan which will facilitate the effective transition from junior clinical investigator to research scientist. She provides a detailed description of her own augmentation of further training in clinical trial implementation. Her current research projects are thematically linked through their focus on molecular and immunologic determinants of sarcoidosis clinical outcome for the purpose of identifying novel therapeutic interventions. In particular, her research focuses on the contribution of mycobacterial induction of T cell dysfunction to sarcoidosis disease progression, and the capacity of antimycobacterial therapy to restore T cell function. Trainees have been involved in many aspects of the ongoing patient-oriented research including study design, patient accrual, data collection, laboratory assays and analysis and presentation of findings. The transformative nature of the proposal to investigate the therapeutic utility of PD-1 is that it allows translation of molecular mechanisms identified at the bench to immune function within the host, and ultimately to a clinical endpoint associated with sarcoidosis mortality, absolute FVC.

 描述（由申请人提供）：这是一项旨在为Dr. Drake提供保护时间的提案，以便为初级临床研究者提供更多指导，并提高其扩展间质性肺病临床研究的能力。Drake博士提出了一项指导计划，该计划将促进从初级临床研究者到研究科学家的有效过渡。她详细描述了她自己在临床试验实施方面的进一步培训。她目前的研究项目是通过他们的重点结节病临床结果的分子和免疫学决定因素，以确定新的治疗干预措施的目的主题联系。特别是，她的研究重点 关于分枝杆菌诱导T细胞功能障碍对结节病疾病进展的贡献，以及抗分枝杆菌治疗恢复T细胞功能的能力。受训人员参与了正在进行的以患者为导向的研究的许多方面，包括研究设计、患者招募、数据收集、实验室测定和分析以及结果介绍。研究PD-1治疗效用的提案的变革性质是，它允许将实验室确定的分子机制转化为宿主内的免疫功能，并最终转化为与结节病死亡率（绝对FVC）相关的临床终点。